Kidney transplant recipients develop disorders of mineral and bone metabolism that further impair bone strength, leading to osteoporosis and a high fracture risk. However, evidence in this setting is limited. Romosozumab, a sclerostin inhibitor with both anabolic and antiresorptive effects, is an attractive option, but...
Simona Barbuto, Paolo Mastromauro, G. Zavatta et al.· Frontiers in Endocrinology· 0 citations
In patients with acromegaly, TBS is associated with prevalent but not incident vertebral fractures, and periodic vertebral morphometric assessment remains essential for early fracture detection and fracture risk stratification.
F. Bioletto, M. Sibilla, M. Barale et al.· European Journal of Endocrin...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.